Skip to main content
. Author manuscript; available in PMC: 2021 Oct 21.
Published in final edited form as: Sci China Life Sci. 2012 Aug 4;55(7):576–590. doi: 10.1007/s11427-012-4339-2

Figure 3.

Figure 3

Systemic increases of myeloid cells in c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice. A, Single cell suspensions were prepared from the bone marrow, blood (PBMC), spleen and lung of 3-month doxycycline-treated and untreated bitransgenic mice for FACS analyses. Distribution of CD11b+ macrophage and GR-1+ cells was presented in dot plots. Each experiment represents 3 independent (n=3) studies. –DOX, doxycycline-untreated bitransgenic mice; +DOX, doxycycline-treated bitransgenic mice. B, C-fms-rtTA/(TetO)7-CMV-Stat3 bitransgenic mice were treated or untreated with doxcycline for 10–15 months. Lungs were inflated, sectioned and analyzed by H&E staining.